Follow The Filings

ANGO AngioDynamics

AngioDynamics earnings company data as of 4:47 AM ET 11/22

  • 1 of 1 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2027 Q2 5 Jan EPS — — —
Rev — — —
FY2027 Q1 8 Oct EPS -0.11 -0.04 Beat
Rev $80.5M $80.9M In line +0.5%

Insider trades

Open-market buys and sales by ANGO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ANGO insider trades
  • None no insider bought on the open market
  • $655K sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Stephen A. Trowbridge CFO
    Sale
    $311K 25,335 shares at $12.26 8.3% of stake
    Traded Oct 28–29 Filed Oct 30
  2. Warren Nighan Jr. SVP Quality and Regulatory
    Sale
    $344K 23,370 shares at $14.72 27% of stake
    Traded Jul 30 Filed Jul 31
  3. Lawrence T. Weiss SVP, Chief Legal Officer
    Buy
    $118K 10,000 shares at $11.81 +12% to stake
    Traded Oct 21, 2025 Filed Oct 22, 2025
  4. Stephen A. Trowbridge CFO
    Buy
    $9,932 890 shares at $11.16 +0.3% to stake
    Traded Oct 13, 2025 Filed Oct 14, 2025
  5. James C. Clemmer CEO
    Buy
    $112K 10,000 shares at $11.15 +1.1% to stake
    Traded Oct 9, 2025 Filed Oct 9, 2025

Also filed in the last 12 months, not counted as buying or selling: 23 share withholdings for taxes, 14 stock grants, and 5 option exercises.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 5.02,5.07,9.01
SCHEDULE 13G/A —
DEF 14A
10-Q
DEFA14A
8-K 2.02,7.01,9.01
8-K 1.01,5.02,9.01
10-K/A
10-K/A
8-K 2.02,7.01,9.01
10-K
SCHEDULE 13G/A —
8-K 8.01
10-Q

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf